Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Andrej Janzic"'
Autor:
Urska Janzic, Andrej Janzic, Abed Agbarya, Urska Bidovec-Stojkovic, Katja Mohorcic, Marina Caks, Peter Korosec, Matija Rijavec, Erik Skof
Publikováno v:
Biomedicines, Vol 12, Iss 3, p 535 (2024)
Due to the devastating COVID-19 pandemic, a preventive tool in the form of vaccination was introduced. Thoracic cancer patients had one of the highest rates of morbidity and mortality due to COVID-19 disease, but the lack of data about the safety and
Externí odkaz:
https://doaj.org/article/5de58b0a87b34b86add7f954bc71968c
Publikováno v:
BMC Health Services Research, Vol 18, Iss 1, Pp 1-13 (2018)
Abstract Background Rational and transparent Health Technology Assessment and reimbursement decision-making are crucial for healthcare system sustainability. A part of the reimbursement process are decision-making criteria which should be clearly def
Externí odkaz:
https://doaj.org/article/0e525f03693b4150a362c79aac652c55
Publikováno v:
Radiology and Oncology
Radiology and oncology (Ljubljana)
Radiology and Oncology, Vol 51, Iss 3, Pp 357-362 (2017)
Radiology and oncology (Ljubljana)
Radiology and Oncology, Vol 51, Iss 3, Pp 357-362 (2017)
BackgroundWith introduction of immunotherapy (IT) into the treatment of advanced non-small-cell lung cancer (NSCLC), a need for predictive biomarker became apparent. Programmed death ligand 1 (PD-L1) protein expression is most widely explored predict
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dac72f52d4464030fbc370c876d3eadf
http://europepmc.org/articles/PMC5612001
http://europepmc.org/articles/PMC5612001
Autor:
Andrej Janzic, Mitja Kos
Publikováno v:
Acta Pharmaceutica
Volume 67
Issue 3
Acta Pharmaceutica, Vol 67, Iss 3, Pp 397-406 (2017)
Volume 67
Issue 3
Acta Pharmaceutica, Vol 67, Iss 3, Pp 397-406 (2017)
Anticoagulation treatment was recently improved by the introduction of novel oral anticoagulants (NOACs). Using a combination of qualitative and quantitative methods, this study explores the effects of the introduction of NOACs on anticoagulation car
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d32f7fbf4ad2ee776a29d7f09a466ac
https://doi.org/10.1515/acph-2017-0030
https://doi.org/10.1515/acph-2017-0030
Publikováno v:
Expert review of pharmacoeconomicsoutcomes research. 19(6)
Objectives: Timely access to novel anticancer drugs is challenging and value frameworks such as the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) could assist...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e86fc54219d21610fb599250e075611f
https://pubmed.ncbi.nlm.nih.gov/31826655
https://pubmed.ncbi.nlm.nih.gov/31826655
Publikováno v:
Journal of Thoracic Oncology. 14:S557-S558
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44b17789eb150c7657cf675c87dff4a4
https://doi.org/10.1016/j.jtho.2019.08.1165
https://doi.org/10.1016/j.jtho.2019.08.1165
Publikováno v:
American journal of cardiovascular drugs : drugs, devices, and other interventions. 17(5)
After early clinical trials that evaluated pharmacogenetic (PG) algorithms, many healthcare payers were reluctant to cover this technology and, consequently, PG dosing of warfarin could not be translated into clinical practice. The aim of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68aa39b9e510e80971aff1f351d0552c
https://pubmed.ncbi.nlm.nih.gov/28528365
https://pubmed.ncbi.nlm.nih.gov/28528365
Publikováno v:
Annals of Oncology. 29:viii565
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::018020ed92b954169d1dbdf4debf961a
https://doi.org/10.1093/annonc/mdy297.009
https://doi.org/10.1093/annonc/mdy297.009
Publikováno v:
Journal of Thoracic Oncology. 11:S58-S59
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d6451b68aee34c785f3f20e59757a51
https://doi.org/10.1016/s1556-0864(16)30120-4
https://doi.org/10.1016/s1556-0864(16)30120-4